Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA oncology division director

Executive Summary

FDA appoints Robert Justice as director of the Division of Drug Oncology Products within FDA's Office of Oncology Drug Products, effective June 11. Justice had been acting director of the division since it became operational as part of a July 2005 CDER reorganization (1"The Pink Sheet" June 27, 2005, p. 11). Justice has held several positions within the agency since 1985 and was a senior clinical scientist at Genentech from 2000-2002...

You may also be interested in...



FDA Oncology Drug Reviews Headed By Justice Under Revised Structure

Deputy director of FDA's biological oncology product review team Robert Justice will head the Division of Drug Oncology Products under the reorganization of the Office of New Drugs

Pink Sheet Podcast: COVID Vaccine In Adolescents, CMS Drug Pricing Moves, Standard Care In Clinical Trials

Pink Sheet reporters and editors discuss the US FDA decision to lower the eligibility age for the Pfizer/BioNTech COVID-19 vaccine, CMS drug pricing project plans, and mid-stream standard of care changes in drug development.

Keeping Track: US FDA Approves Heron’s Zynrelef In Post-Op Pain; Amgen/AZ Submit Tezepelumab For Severe Asthma

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

UsernamePublicRestriction

Register

PS047224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel